FOXC2 has also recently emerged as a potential biomarker linked to the progression of several cancers and is associated with tumor cell proliferation, drug resistance, and initiation of the epithelial-mesenchymal transition (EMT) that takes place before cancer cell invasion and metastasis (Hargadon and Strong, 2023; Mani et al., 2007; Zhang et al., 2022). This evidence concerns the gene FOXC2 and cancer.